Activin and TGFβ Use Diverging Mitogenic Signaling in Advanced Colon Cancer

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2015 Oct 27

PMID 26497569

Citations 46

Authors

Jessica Bauer

Ozkan Ozden

Naomi Akagi

Timothy Carroll

Daniel R Principe

Jonas J Staudacher

Martina E Spehlmann

Lars Eckmann

Paul J Grippo

Barbara Jung

Affiliations

Soon will be listed here.

Abstract

Background: Understanding cell signaling pathways that contribute to metastatic colon cancer is critical to risk stratification in the era of personalized therapeutics. Here, we dissect the unique involvement of mitogenic pathways in a TGFβ or activin-induced metastatic phenotype of colon cancer.

Method: Mitogenic signaling/growth factor receptor status and p21 localization were correlated in primary colon cancers and intestinal tumors from either AOM/DSS treated ACVR2A (activin receptor 2) -/- or wild type mice. Colon cancer cell lines (+/- SMAD4) were interrogated for ligand-induced PI3K and MEK/ERK pathway activation and downstream protein/phospho-isoform expression/association after knockdown and pharmacologic inhibition of pathway members. EMT was assessed using epithelial/mesenchymal markers and migration assays.

Results: In primary colon cancers, loss of nuclear p21 correlated with upstream activation of activin/PI3K while nuclear p21 expression was associated with TGFβ/MEK/ERK pathway activation. Activin, but not TGFβ, led to PI3K activation via interaction of ACVR1B and p85 independent of SMAD4, resulting in p21 downregulation. In contrast, TGFβ increased p21 via MEK/ERK pathway through a SMAD4-dependent mechanism. While activin induced EMT via PI3K, TGFβ induced EMT via MEK/ERK activation. In vivo, loss of ACVR2A resulted in loss of pAkt, consistent with activin-dependent PI3K signaling.

Conclusion: Although activin and TGFβ share growth suppressive SMAD signaling in colon cancer, they diverge in their SMAD4-independent pro-migratory signaling utilizing distinct mitogenic signaling pathways that affect EMT. p21 localization in colon cancer may determine a dominant activin versus TGFβ ligand signaling phenotype warranting further validation as a therapeutic biomarker prior to targeting TGFβ family receptors.

Citing Articles

Decoupling chemical and mechanical signaling in colorectal cancer cell migration.

Tetrick M, Emon M, Doha U, Marcellus M, Symanski J, Ramanathan V Sci Rep. 2025; 15(1):4952.

PMID: 39929899 PMC: 11811049. DOI: 10.1038/s41598-025-89152-4.

PDCD10 promotes the tumor-supporting functions of TGF-β in pancreatic cancer.

Zhou Q, Breitkopf-Heinlein K, Gaitantzi H, Birgin E, Reissfelder C, Rahbari N Clin Sci (Lond). 2024; 138(18):1111-1129.

PMID: 39212293 PMC: 11405861. DOI: 10.1042/CS20240450.

Epicardial EMT and cardiac repair: an update.

Foglio E, DAvorio E, Nieri R, Russo M, Limana F Stem Cell Res Ther. 2024; 15(1):219.

PMID: 39026298 PMC: 11264588. DOI: 10.1186/s13287-024-03823-z.

Activin A signaling stimulates neutrophil activation and macrophage migration in pancreatitis.

Wiley M, Bauer J, Alvarez V, Mehrotra K, Cheng W, Kolics Z Sci Rep. 2024; 14(1):9382.

PMID: 38654064 PMC: 11039671. DOI: 10.1038/s41598-024-60065-y.

Activin A levels are raised during human tuberculosis and blockade of the activin signaling axis influences murine responses to infection.

Nieuwenhuizen N, Nouailles G, Sutherland J, Zyla J, Pasternack A, Heyckendorf J mBio. 2024; 15(3):e0340823.

PMID: 38376260 PMC: 10936190. DOI: 10.1128/mbio.03408-23.

References

Jung B, Gomez J, Chau E, Cabral J, Lee J, Anselm A . Activin signaling in microsatellite stable colon cancers is disrupted by a combination of genetic and epigenetic mechanisms. PLoS One. 2009; 4(12):e8308. PMC: 2789408. DOI: 10.1371/journal.pone.0008308. View

Liu M, Casimiro M, Wang C, Shirley L, Jiao X, Katiyar S . p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proc Natl Acad Sci U S A. 2009; 106(45):19035-9. PMC: 2776463. DOI: 10.1073/pnas.0910009106. View

Xu J, Acharya S, Sahin O, Zhang Q, Saito Y, Yao J . 14-3-3ζ turns TGF-β's function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2. Cancer Cell. 2015; 27(2):177-92. PMC: 4325275. DOI: 10.1016/j.ccell.2014.11.025. View

de Lima M, Marques Y, de Melo Alves Jr S, Freitas V, Soares F, de Araujo V . MDM2, P53, P21WAF1 and pAKT protein levels in genesis and behaviour of adenoid cystic carcinoma. Cancer Epidemiol. 2009; 33(2):142-6. DOI: 10.1016/j.canep.2009.04.016. View

Chen Y, Lebrun J, Vale W . Regulation of transforming growth factor beta- and activin-induced transcription by mammalian Mad proteins. Proc Natl Acad Sci U S A. 1996; 93(23):12992-7. PMC: 24034. DOI: 10.1073/pnas.93.23.12992. View

Massague J . TGFbeta in Cancer. Cell. 2008; 134(2):215-30. PMC: 3512574. DOI: 10.1016/j.cell.2008.07.001. View

Thiery J, Acloque H, Huang R, Nieto M . Epithelial-mesenchymal transitions in development and disease. Cell. 2009; 139(5):871-90. DOI: 10.1016/j.cell.2009.11.007. View

Grady W, Carethers J . Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 2008; 135(4):1079-99. PMC: 2866182. DOI: 10.1053/j.gastro.2008.07.076. View

Ansieau S, Bastid J, Doreau A, Morel A, Bouchet B, Thomas C . Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell. 2008; 14(1):79-89. DOI: 10.1016/j.ccr.2008.06.005. View

10.

Chow J, Cabral J, Chang J, Carethers J . TGFbeta modulates PTEN expression independently of SMAD signaling for growth proliferation in colon cancer cells. Cancer Biol Ther. 2008; 7(10):1694-9. PMC: 2820113. DOI: 10.4161/cbt.7.10.6665. View

11.

Fleming N, Jorissen R, Mouradov D, Christie M, Sakthianandeswaren A, Palmieri M . SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Cancer Res. 2012; 73(2):725-35. DOI: 10.1158/0008-5472.CAN-12-2706. View

12.

Barrallo-Gimeno A, Nieto M . The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development. 2005; 132(14):3151-61. DOI: 10.1242/dev.01907. View

13.

Vivanco I, Sawyers C . The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2(7):489-501. DOI: 10.1038/nrc839. View

14.

Massague J . TGFβ signalling in context. Nat Rev Mol Cell Biol. 2012; 13(10):616-30. PMC: 4027049. DOI: 10.1038/nrm3434. View

15.

Chen Y, Lui H, Lin S, Lee J, Ying S . Regulation of cell proliferation, apoptosis, and carcinogenesis by activin. Exp Biol Med (Maywood). 2002; 227(2):75-87. DOI: 10.1177/153537020222700201. View

16.

Gray P, Greenwald J, Blount A, Kunitake K, Donaldson C, Choe S . Identification of a binding site on the type II activin receptor for activin and inhibin. J Biol Chem. 2000; 275(5):3206-12. DOI: 10.1074/jbc.275.5.3206. View

17.

Togashi Y, Kogita A, Sakamoto H, Hayashi H, Terashima M, De Velasco M . Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer. Cancer Lett. 2014; 356(2 Pt B):819-27. DOI: 10.1016/j.canlet.2014.10.037. View

18.

Liu P, Cheng H, Roberts T, Zhao J . Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009; 8(8):627-44. PMC: 3142564. DOI: 10.1038/nrd2926. View

19.

Tol J, Koopman M, Cats A, Rodenburg C, Creemers G, Schrama J . Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009; 360(6):563-72. DOI: 10.1056/NEJMoa0808268. View

20.

McCubrey J, Steelman L, Abrams S, Lee J, Chang F, Bertrand F . Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul. 2006; 46:249-79. DOI: 10.1016/j.advenzreg.2006.01.004. View